+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Identification of Gal(beta 1-3)GalNAc bearing glycoproteins in cerebrospinal fluid of amyotrophic lateral sclerosis (ALS) patients



Identification of Gal(beta 1-3)GalNAc bearing glycoproteins in cerebrospinal fluid of amyotrophic lateral sclerosis (ALS) patients



European Journal of Neurology 7(6): 679-683



Glycoproteins in cerebrospinal fluid of 55 patients with amyotrophic lateral sclerosis (ALS), six disease controls (multifocal motor neuropathy, sensorimotor neuropathy, Guillain-Barré syndrome, spinal muscular atrophy type II, motor neuropathy with monoclonal gammopathy) and 20 healthy controls were separated by PAGE electrophoresis and then detected immunochemically with peanut agglutinin (PNA). In 36 amyotrophic lateral sclerosis patients the 262 kDa glycoprotein was significantly increased (over the normal mean +/- SD x 2), which was associated with a decrease in the 114 kDa fraction. In the remaining patients, both fractions were either equal in concentration or the 114 kDa glycoprotein predominated. In normal cerebrospinal fluid, the 114 kDa glycoprotein predominated over the other glycoproteins. The total amount of separated glycoproteins was increased in 15 amyotrophic lateral sclerosis patients. In 12 of them it was followed by an increase in the percentage of the 262 kDa glycoprotein. There was no correlation between the content of the peanut agglutinin-labelled glycoproteins and the patients' age, duration and severity of the disease. There was a correlation between the 262 kDa glycoprotein being increased in cerebrospinal fluid and the electrophysiological pattern of denervation seen in electromyographic study. The glycoproteins change, similar to that occurring in amyotrophic lateral sclerosis patients, was also observed in one case of multifocal motor neuropathy (MMN). We suggest that in amyotrophic lateral sclerosis and multifocal motor neuropathy, the peanut agglutinin-labelled glycoproteins are released in excess from the nervous tissues into the cerebrospinal fluid as a result of neuronal degeneration. The question to be answered is, whether the released glycoproteins are becoming targets for auto-antibodies.

(PDF emailed within 1 workday: $29.90)

Accession: 046312204

Download citation: RISBibTeXText

PMID: 11136355


Related references

Structure of the monosialyl oligosaccharides derived from sa-livary gland mucin glycoproteins of the Chinese swiftlet genus Collocalia Characterization of novel types of extended core structure, Gal1-3 1-6 GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc GalNAc. Journal of Biological Chemistry, 26214: 6650-6657, 1987

Identification of miRNAs as Potential Biomarkers in Cerebrospinal Fluid from Amyotrophic Lateral Sclerosis Patients. Neuromolecular Medicine 18(4): 551-560, 2016

Concentrations of beta-amyloid precursor protein processing products in cerebrospinal fluid of patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Journal of Neural Transmission 116(9): 1169-1178, 2009

Identification of biomarkers for amyotrophic lateral sclerosis by comprehensive analysis of exosomal mRNAs in human cerebrospinal fluid. Bmc Medical Genomics 12(1): 7-7, 2019

Tau protein concentrations in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neurologica Scandinavica 111(2): 114-117, 2005

Chromogranin A levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Neurobiology of Aging 67: 21-22, 2018

T4, T3 and rT3 levels in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Journal of Neurology 236(1): 57-59, 1989

High levels of C3c in the cerebrospinal fluid from amyotrophic lateral sclerosis patients. Acta Neurologica Scandinavica 72(1): 61-64, 1985

Chromogranin A levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Neurobiology of Aging 67: 21-22, 2018

Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neuropathologica 117(1): 55-62, 2008

Cerebrospinal fluid angiogenin level in patients with amyotrophic lateral sclerosis. Acta Clinica Croatica 47(2): 77-79, 2008

Immunological studies of the cerebrospinal fluid in patients with amyotrophic lateral sclerosis. Zhurnal Nevropatologii i Psikhiatrii Imeni S.S. Korsakova 91(2): 29, 1991

Calcitonin level in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Polski Tygodnik Lekarski 47(14-15): 310-311, 1992

Erythropoietin concentration in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Journal of Neural Transmission 117(3): 343-347, 2010

Elevation of MCP-1 and MCP-1/VEGF ratio in cerebrospinal fluid of amyotrophic lateral sclerosis patients. Neurological Research 29(8): 772-776, 2007